Arrowhead Pharmaceuticals Inc (ARWR)
22.08
+0.21
(+0.96%)
USD |
NASDAQ |
Apr 26, 15:09
Arrowhead Pharmaceuticals Cash from Financing (Quarterly): 0.267M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.267M |
| September 30, 2023 | 0.152M |
| June 30, 2023 | 1.805M |
| March 31, 2023 | 0.52M |
| December 31, 2022 | 250.58M |
| September 30, 2022 | 0.855M |
| June 30, 2022 | 60.60M |
| March 31, 2022 | 1.846M |
| December 31, 2021 | 1.885M |
| September 30, 2021 | 0.815M |
| June 30, 2021 | 2.755M |
| March 31, 2021 | 2.633M |
| December 31, 2020 | 5.102M |
| September 30, 2020 | 1.005M |
| June 30, 2020 | 2.132M |
| March 31, 2020 | 1.333M |
| December 31, 2019 | 253.48M |
| September 30, 2019 | 1.833M |
| June 30, 2019 | 2.767M |
| March 31, 2019 | 2.67M |
| December 31, 2018 | 59.11M |
| September 30, 2018 | 1.571M |
| June 30, 2018 | 1.454M |
| March 31, 2018 | 56.90M |
| December 31, 2017 | 0.0263M |
| Date | Value |
|---|---|
| September 30, 2017 | -0.1223M |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.1421M |
| December 31, 2016 | 12.04M |
| September 30, 2016 | 53.64M |
| June 30, 2016 | 2.205M |
| March 31, 2016 | -0.2224M |
| December 31, 2015 | -0.4946M |
| September 30, 2015 | 0.1369M |
| June 30, 2015 | -0.0535M |
| March 31, 2015 | 0.0268M |
| December 31, 2014 | 0.1803M |
| September 30, 2014 | 0.5358M |
| June 30, 2014 | 4.342M |
| March 31, 2014 | 117.65M |
| December 31, 2013 | 62.77M |
| September 30, 2013 | 2.003M |
| June 30, 2013 | 35.31M |
| March 31, 2013 | 3.703M |
| December 31, 2012 | 3.279M |
| September 30, 2012 | 5.504M |
| June 30, 2012 | 2.653M |
| March 31, 2012 | 1.181M |
| December 31, 2011 | 1.432M |
| September 30, 2011 | 4.45M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.152M
Minimum
Sep 2023
253.48M
Maximum
Dec 2019
31.18M
Average
1.846M
Median
Mar 2022
Cash from Financing (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | 479.92M |
| Viking Therapeutics Inc | 606.04M |
| Akero Therapeutics Inc | 0.502M |
| 89bio Inc | 162.17M |
| Sagimet Biosciences Inc | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -117.84M |
| Cash from Investing (Quarterly) | 64.84M |
| Free Cash Flow | -402.70M |
| Free Cash Flow Per Share (Quarterly) | -1.736 |
| Free Cash Flow to Equity (Quarterly) | -186.50M |
| Free Cash Flow to Firm (Quarterly) | -183.99M |
| Free Cash Flow Yield | -16.97% |